OBJECTIVE: To characterize the effect of efavirenz on bupropion hydroxylation as a marker of cytochrome P450 (CYP) 2B6 activity in healthy subjects. METHODS: Thirteen subjects received a single oral dose of bupropion SR 150 mg before and after 2 weeks of efavirenz administration for comparison of bupropion and hydroxybupropion pharmacokinetics. Efavirenz plasma concentrations were also assessed. Subjects were genotyped for CYP2B6 (G516T, C1459T, and A785G), CYP3A4 (A-392G), CYP3A5 (A6986G), and multidrug resistance protein 1 (C3435T). RESULTS: The area under the concentration vs. time curve ratio of hydroxybupropion:bupropion increased 2.3-fold after efavirenz administration (P=0.0001). Bupropion area under the concentration vs. time curve and Cmax decreased by 55% and 34%, respectively (P<0.002). None of the CYP2B6 or CYP3A genotypes evaluated were associated with a difference in bupropion or efavirenz clearance. The 2 individuals homozygous for multidrug resistance protein 1 3435-T/T had 2.5- and 1.8-fold greater bupropion and efavirenz clearance, respectively, relative to C/C and C/T individuals (P<0.05). CONCLUSIONS: Our results confirm that efavirenz induces CYP2B6 enzyme activity in vivo, as demonstrated by an increase in bupropion hydroxylation after 2 weeks of efavirenz administration.
OBJECTIVE: To characterize the effect of efavirenz on bupropion hydroxylation as a marker of cytochrome P450 (CYP) 2B6 activity in healthy subjects. METHODS: Thirteen subjects received a single oral dose of bupropion SR 150 mg before and after 2 weeks of efavirenz administration for comparison of bupropion and hydroxybupropion pharmacokinetics. Efavirenz plasma concentrations were also assessed. Subjects were genotyped for CYP2B6 (G516T, C1459T, and A785G), CYP3A4 (A-392G), CYP3A5 (A6986G), and multidrug resistance protein 1 (C3435T). RESULTS: The area under the concentration vs. time curve ratio of hydroxybupropion:bupropion increased 2.3-fold after efavirenz administration (P=0.0001). Bupropion area under the concentration vs. time curve and Cmax decreased by 55% and 34%, respectively (P<0.002). None of the CYP2B6 or CYP3A genotypes evaluated were associated with a difference in bupropion or efavirenz clearance. The 2 individuals homozygous for multidrug resistance protein 1 3435-T/T had 2.5- and 1.8-fold greater bupropion and efavirenz clearance, respectively, relative to C/C and C/T individuals (P<0.05). CONCLUSIONS: Our results confirm that efavirenz induces CYP2B6 enzyme activity in vivo, as demonstrated by an increase in bupropion hydroxylation after 2 weeks of efavirenz administration.
Authors: Katarzyna K Loboz; Annette S Gross; Kenneth M Williams; Winston S Liauw; Richard O Day; Julia K Blievernicht; Ulrich M Zanger; Andrew J McLachlan Journal: Clin Pharmacol Ther Date: 2006-07 Impact factor: 6.875
Authors: S R Faucette; R L Hawke; E L Lecluyse; S S Shord; B Yan; R M Laethem; C M Lindley Journal: Drug Metab Dispos Date: 2000-10 Impact factor: 3.922
Authors: Jacqueline Ramírez; Federico Innocenti; Erin G Schuetz; David A Flockhart; Mary V Relling; Raymond Santucci; Mark J Ratain Journal: Drug Metab Dispos Date: 2004-09 Impact factor: 3.922
Authors: Marc Pfister; Line Labbé; Scott M Hammer; John Mellors; Kara K Bennett; Susan Rosenkranz; Lewis B Sheiner Journal: Antimicrob Agents Chemother Date: 2003-01 Impact factor: 5.191
Authors: Alan R Lifson; Jacqueline Neuhaus; Jose Ramon Arribas; Mary van den Berg-Wolf; Ann M Labriola; Timothy R H Read Journal: Am J Public Health Date: 2010-08-19 Impact factor: 9.308
Authors: R Douglas Bruce; David E Moody; Frederick L Altice; Marc N Gourevitch; Gerald H Friedland Journal: Expert Rev Clin Pharmacol Date: 2013-05 Impact factor: 5.045